News & Media

Take a look inside our world

Press Releases

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conf...

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferenc

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississipp...

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, an

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risper...

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class P...

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potent

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-...

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Prop...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarte...

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Pro...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept...

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in
View all press releases
Previous
Next

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Feature stories

All Access to Medicine Biologics Biosimilars Caregivers Environment Generic Medicines Global Operations Immunology Innovation Leadership Inclusion & Diversity Neuroscience Our People Patient Focus Quality Research & Development Respiratory Sustainability Wellbeing Working at Teva

3 Trends I’m Watching in Clinical Research Studies

3 Trends I’m Watching in Clinical Research Studies

“Real Progress Comes Not from Extraordinary Moments but from the Everyday”

“Real Progress Comes Not from Extraordinary Moments but from the Everyday”

Addressing the Unmet Needs of Inflammatory Bowel Disease Patients

Addressing the Unmet Needs of Inflammatory Bowel Disease Patients

Why Diversity in Clinical Trials is So Important

Why Diversity in Clinical Trials is So Important

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Living With an Invisible Disability: What We All Need to Know

Living With an Invisible Disability: What We All Need to Know

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

A Passport to Career Development: A Journey with Teva's R&D Teams

A Passport to Career Development: A Journey with Teva's R&D Teams

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance
View all stories

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com

View our Social Media Guidelines

Learn more